To provide the information your oncologist is not telling you or doesn't have the time to!
Stay Informed About the Latest Oncology Breakthroughs
Explore the forefront of oncological research with our “Research Advances” category. Discover cutting-edge studies, innovative treatments, and scientific insights into cancer. Stay up-to-date with the latest breakthroughs and advancements in the field of oncology to make informed decisions about your health or that of your loved ones. Dive into the world of scientific progress and gain a deeper understanding of how research is shaping the future of cancer care.
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and challenging types of thyroid cancer. Known for its rapid growth, resistance to conventional therapies, and poor prognosis, ATC has historically had limited treatment options. However, recent studies, including groundbreaking research by Dr. Maria Cabanillas and colleagues at MD Anderson Cancer Center, have highlighted the …
In the world of oncology, chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of certain B-cell malignancies like lymphomas and leukemias. But a recent study in The New England Journal of Medicine has opened the door to an entirely new application: using CAR T-cell therapy to treat severe autoimmune diseases such as systemic lupus erythematosus …
Multiple myeloma (MM) is a type of blood cancer originating in the plasma cells of the bone marrow, leading to an overproduction of abnormal plasma cells. This accumulation disrupts normal blood cell production and results in a range of complications, such as bone pain, anemia, kidney issues, and increased infection risk. Historically, treatment options for …
Prostate cancer continues to pose a significant challenge for both patients and healthcare providers. In the realm of radiation therapy, the development of advanced techniques has transformed the landscape of treatment. A recent phase 3 trial comparing Stereotactic Body Radiotherapy (SBRT) to conventional radiotherapy for intermediate-risk prostate cancer provides new insights into how we can deliver effective …
The treatment landscape for advanced-stage classic Hodgkin’s lymphoma (cHL) is rapidly evolving. Traditionally, chemotherapy regimens such as AVD (doxorubicin, vinblastine, dacarbazine) or combinations including brentuximab vedotin have been used to manage this challenging disease. However, a groundbreaking phase 3 clinical trial (S1826) has introduced a promising new regimen—nivolumab (N+AVD)—that is proving to be superior in …
On October 18, 2024, the U.S. Food and Drug Administration (FDA) approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a novel treatment for adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval brings a much-needed new option for patients whose tumors express the CLDN18.2 protein, as identified through an FDA-approved test. …
A new article published in the NEJM showing impressive efficacy in NSCLC, here’s the summary below. The landscape of non-small cell lung cancer (NSCLC) treatment continues to evolve, particularly for patients with EGFR mutations. Historically, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib have been the first line of defense, providing improved progression-free survival for patients. …
Hope for Advanced Bladder Cancer Bladder cancer is often like an unwelcome party crasher, popping up when least expected and causing considerable distress. Yet, in the realm of oncology, we are constantly seeking new ways to send such unwelcome guests packing. Today, I am thrilled to share some exciting news about a promising new approach …
Immunotherapy has made significant strides in cancer treatment, but microsatellite stable (MSS) metastatic colorectal cancer (mCRC) has long posed a challenge due to its resistance to immune-based therapies. However, promising results from a recent phase 2/3 trial have shown that the individualized neoantigen-directed immunotherapy, GRANITE, may change the outlook for patients with MSS mCRC. This innovative therapy, combined …
On October 10, 2024, the FDA approved a new and promising treatment for patients with advanced breast cancer: inavolisib (Itovebi), in combination with palbociclib and fulvestrant. This new approval offers fresh hope for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, and HER2-negative breast cancer, especially those whose disease has progressed after endocrine therapy. The approval also includes the FoundationOne Liquid CDx assay, a diagnostic test used to …